1. Volume 375, Issue 9715, Pages 641-648 (February 2010)
Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial 
Prof Martin E Gore, MD, Clare L Griffin, MSc, Prof Barry Hancock, MD, Prof Poulam M Patel, PhD, Lynda Pyle, BSc, Michael Aitchison, MD, Prof Nicholas James, PhD, Prof Roderick TD Oliver, MD, Jozef Mardiak, MD, Tahera Hussain, DPhil, Richard Sylvester, ScD, Prof Mahesh KB Parmar, DPhil, Prof Patrick Royston, DSc, Prof Peter FA Mulders, MD 
The Lancet 
Volume 375, Issue 9715, Pages (February 2010)
DOI: /S (09)
Copyright © 2010 Elsevier Ltd Terms and Conditions

2. Figure 1
Trial profile
Screening logs were not used, so the number of patients assessed for eligibility was not available.
The Lancet  , DOI: ( /S (09) )
Copyright © 2010 Elsevier Ltd Terms and Conditions

3. Figure 2
Kaplan-Meier plots of (A) overall survival and (B) progression-free survival for patients receiving interferon alfa-2a or combined treatment*
*With interferon alfa-2a, interleukin-2, and fluorouracil.
The Lancet  , DOI: ( /S (09) )
Copyright © 2010 Elsevier Ltd Terms and Conditions

4. Figure 3
Absolute difference between treatments for (A) overall survival and (B) progression-free survival
Values greater than zero show improved survival with combined treatment. 95% CIs are for the difference between treatment with interferon alfa-2a alone and combined treatment with interferon alfa-2a, interleukin-2, and fluorouracil. Red line shows no difference between treatment groups. KM=Kaplan-Meier.
The Lancet  , DOI: ( /S (09) )
Copyright © 2010 Elsevier Ltd Terms and Conditions